
Summit Therapeutics stock plunges after FDA rejects lung cancer drug
Summary
Shares of Summit Therapeutics experienced a sharp decline following the decision by regulatory authorities not to approve the company's new treatment for lung cancer. The setback occurred after the health agency formally rejected the pharmaceutical application.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.